Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 12/20 | 0.47 |
| ▸ | APOB | P04114 | 7/20 | 0.47 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7039849 | 0.86 | APOB (0.50) | MTTPAPOBKDM4E | |
| SCHEMBL7041153 | 0.85 | MTTP (0.45) | MTTPAPOBKDM4E | |
| SCHEMBL7042807 | 0.84 | MTTP (0.49) | MTTPAPOBKDM4E | |
| SCHEMBL7042911 | 0.84 | MTTP (0.50) | MTTPAPOBKDM4E | |
| SCHEMBL7041367 | 0.83 | MTTP (0.48) | MTTPAPOB | |
| SCHEMBL7039772 | 0.83 | MTTP (0.53) | MTTPAPOB | |
| SCHEMBL7043296 | 0.83 | MTTP (0.57) | MTTPAPOB | |
| SCHEMBL7038711 | 0.83 | MTTP (0.51) | MTTPAPOBKDM4E | |
| SCHEMBL7040057 | 0.82 | MTTP (0.53) | MTTPAPOB | |
| SCHEMBL6278519 | 0.81 | MTTP (0.55) | MTTPAPOBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-28 | — | — | US | disclosed |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | APOB, LIPC, MTPN | MTTP 9/4885APOB 1/4885TRPV4 3693/4885 |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | MTTP, CETP, CES1 | MTTP 1/4885APOB 18/4885TRPV4 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.